The global unit dose manufacturing market size is expected to reach USD 150.61 billion by 2030, registering a CAGR of 11.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. In the first half of 2020, the growth of the market was stagnant, but the market started to recover by the end of 2020. It was mainly due to the use of unit doses for the treatment of COVID-19 as it decreases the risk involved while handling and pouring doses from the same bottle.
Unit dose manufacturing has many advantages as the drug can be easily identified, and the formulation of the drug is protected until the moment of administration. If the container is intact and the drug has not been used, it can be redisposed and retrieved without changing its formulation. The most important benefit is that it can be administered in the proper dosage and ensures that the patient does not exceed the prescribed limit.
However, the COVID-19 pandemic has a significant effect on the pharmaceutical market. The first half of the COVID-19 pandemic had slowed growth but by the end of 2020, the market started to recover. The unit dose manufacturing is lucratively used in the current scenario as it reduces the risk of handling and contamination. Also, unit doses are widely used in hospitals for COVID-19 patients to safeguard both patients and healthcare personnel to eliminate the possibility of viral transmission by airborne transmission or direct touch.
Request a free sample copy or view report summary: Unit Dose Manufacturing Market Report
By sourcing, the outsourcing segment led the market with the largest revenue market share of 60.74% in 2024. Outsourcing services dominated the unit dose manufacturing industry, owing to cost-effectiveness, expertise, flexibility, risk reduction, and access to global markets.
The solid unit dose segment led the market with the largest revenue share of 50.49% in 2024. Solid unit dosage forms such as tablets and capsules dominate unit dose marketing due to their high demand, widespread applications, and patient convenience.
Based on end use, the independent pharmacies segment led the market with the largest revenue share of 39.11% in 2024 and is also anticipated to register at the fastest CAGR over the forecast period.
North America dominated the unit dose manufacturing market with the largest revenue share of 37.73% in 2024. The market revenue growth is driven by the region's advanced healthcare infrastructure, high prevalence of chronic diseases, and strong regulatory focus on patient safety and medication accuracy.
Grand View Research has segmented the global unit dose manufacturing market on the basis of on sourcing, product, end-use, and region:
Unit Dose Manufacturing Sourcing Outlook (Revenue, USD Million, 2018 - 2030)
In-house
Outsourcing
Unit Dose Manufacturing Product Outlook (Revenue, USD Million, 2018 - 2030)
Liquid Unit Dose
Solid Unit Dose
Others
Unit Dose Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
Independent Pharmacies
Long Term Care Facility
Hospitals
Others
Unit Dose Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
Thailand
South Korea
Australia
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Unit Dose Manufacturing Market
Catalent Inc.
Unither Pharmaceuticals
Thermo Fisher Scientific
Corden Pharma
Mikart LLC
LTS LOHMANN Therapie-Systeme AG (TapeMark)
Renaissance Lakewood LLC
Medical Packaging Inc.
American Health Packaging
PCI Pharma Services
Amcor PLC
Bristol-Myers Squibb
AbbVie Inc.
Amgen
West Pharmaceutical Services,
Merck & Co. Inc.
Pfizer Inc.
"The quality of research they have done for us has been excellent..."